

Ergoresearch: A World in Motion

PROFILE

Since 2005, Ergoresearch has developed the most important network of orthotics clinics in Quebec, with over one hundred corporate centres and satellites under the **Clinique du pied Équilibre**, **Orthoconcept** and **Laboratoire Langelier** banners. Ergoresearch proposes innovative, economically efficient orthopedic products and solutions offering peak impact on pain and function that are often reimbursed by third-party payers. Our biomechanical devices are non-invasive and non-toxic, and patient benefits are well documented in a substantial body of clinical proof, with convincing scientific data.

MISSION AND PLEDGE

Our mission is to improve our patients' quality of life. Each of our actions is guided by our desire to help them **IMPROVE THEIR MOBILITY**. Our aim is to reduce pain and rehabilitate motor function with the Company's assorted technologies and vast expertise. We keep the world in motion thanks to a network of skilled professionals equipped with top technological tools.

INNOVATION

The leading manufacturer of «intelligent» custom-fit foot orthotics and specialty orthotics, Ergoresearch is the benchmark for specialty medical equipment and software on the orthopedics market. The Company's patents portfolio ranges from orthotics/prosthesis and neurostimulation to human bionics, including intellectual property rights for the Power Knee – the only motorized prosthesis with artificial intelligence in the world, destined for above-knee amputees.

WHY INVEST IN ERGORESEARCH?


Ergoresearch Ltd is listed on the Toronto Venture Exchange under the ERG symbol. Its five-year growth strategy is ambitious.

- Full-growth profitable Company evolving in an ever-expanding market;
- Markets are in full effervescence owing to:
 - Aging populations and their related joint problems;
 - High incidence of diabetes and obesity;
- Products offer interesting plus-values and superior results in the area of pain relief;
- Strong profit margins draw on the merits of the Company's product lines, and the vertical integration of its assorted activities;
- Features non-invasive orthopedic devices that diminish reliance on medication;
- Products are sold on prescription and are reimbursed by most insurance companies(third-party payers);
- Its patent portfolio encompasses the fields of orthotics and prosthesis, human bionics and neurostimulation. Some products are sold under world license and therefore generate fluxes in royalty revenues for the Company.

RECENT ACHIEVEMENTS

- June 2014: Ranked 129th fastest growing company in Canada;
- May 2014: Development and production of a 3D scanner;
- April 2014: Nomination of Mr Piero Greco to the position of Chief Financial Officer;
- July 2013: Acquisition of Medicare codes (healthcare system administered by the American Government) for the Power Knee bionic prosthesis;
- April 2013: Acquisition of all outstanding Victhom Human Bionics' shares (TSXV: VHB).

CUSTOM FOOT ORTHOTICS




ODRA ORTHOTIC DEVICE



POWER KNEE



NEUROSTIMULATION





ERGORESEARCH



Ergoresearch: A World in Motion

Trading: ERG Toronto Venture Exchange (TSXV)

Fiscal Year-End June 30

Recent Price (June 16 2014) \$0.84

Common Shares Issued 75 722 673

General Information Ergoresearch Ltd 2101 Le Carrefour Blvd, Suite 200 Laval (Quebec) H7S 2J7

Financial Reports www.sedar.com

Transfer Agent Equity Transfer & Trust Company 200 University Avenue, Suite 400 Toronto (Ontario) M5H 4H1

CUSIP NUMBER 29482C

Auditors KPMG s.r.l./S.E.N.C.R.L. Professional Chartered Accountants KPMG Tower, Suite 1500 600 de Maisonneuve Blvd West Montreal (Quebec), H3A 0A3


Investor Relations Please address your requests for information to info@ergoresearch.com

Website www.ergoresearch.com

MOBILE/MEDICAL TECHNOLOGIES

Thanks to the Company's software programs and mobile devices, a patient's condition is quickly assessed and new custom orthotics ordered without ever leaving their physician's office. Ergoresearch's digital technology enables clinicians to travel about easily and meet patients anywhere across their given territory. A bi-modal plantar sensor system offers a detailed podometric assessment combining imagery with foot imprinting data for optimal analysis. A new scanner provides a digital 3D reading in real time of any part of the body, which in turn facilitates the manufacturing process. Orthotics orders are then transmitted via internet to the Company's computational servers, and processed at the manufacturing plant which is almost entirely operated by robotics.

FINANCIAL PERFORMANCE



OVERVIEW

- Largest specialty orthotics sales network in Quebec (Langelier, Orthoconcept and Clinique du pied Équilibre);
- Biomechanical-type products (class 1) which are non-invasive and non-toxic;
- Innovative products and solutions offering superior results in pain management and motor function;
- Well documented clinical proof and convincing scientific data;
- Exclusive OdrA distribution rights in Canada, a revolutionary new patented orthotic device treating knee OA;
- Canada's knee OA market is evaluated at \$3b;
- Mobile and patented technologies exclusive to Ergoresearch;
- Royalty revenues from the Power Knee, a bionic device distributed by Ossür (Victiom patent portfolio);
- The Company has shown constant growth and earnings since 2005. Its an efficient economic engine with recurring revenues;
- Growth strategy vested in innovation paired with an ambitious acquisitions program.



Caution Regarding Forward-Looking Statements – Certain statements in this document, including those that express predictions or estimations regarding the Company's future-looking earnings, represent future-looking statements compliant with applicable securities legislation. While forward-looking statements are based on predictions and hypotheses, the Company considers these factors and assumptions to be reasonable based on information currently available. However, they are inherently subject to uncertainty and represent not insignificant risk on commercial, economic and competitive levels. We caution investors against unduly relying on forward-looking statements. This corporate fact sheet should be read in combination with the Company's financial report and its latest annual report, available at www.sedar.com.